Gilead Plays Hardball With Hep C Patient Assistance
Executive Summary
Gilead Sciences recently began limiting enrollment in its Sovaldi and Harvoni patient assistance program in an attempt to pressure payors to expand their coverage criteria. The big question is how payors are likely to react.
You may also be interested in...
Pharma Survival In A Transforming Global Payer Environment
Economic pressures and technological advances are forcing an unprecedented transformation of the payer environment. Biopharma companies must adjust their market access and pricing strategies to maintain competitively well-positioned and profitable organizations.
The Shrinking Value Of Best-In-Class And First-In-Class Drugs
Incumbency ain’t worth what it once was. Pharma companies are spending billions to create advantages that won’t have significant lasting power. Smart followers can do as well – for less.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.